Brief: Lunit Enters Into Research Collaboration To Explore The Use Of AI To Improve The Effectiveness Of Immunotherapy
Oct 27 (Reuters) - Lunit Inc 328130.KQ :
* LUNIT ENTERS INTO RESEARCH COLLABORATION TO EXPLORE THE
USE OF
AI TO IMPROVE THE EFFECTIVENESS OF IMMUNOTHERAPY
* LUNIT INC - LUNIT TO SUPPORT MD ANDERSON RESEARCHERS
STUDYING
IMMUNE PHENOTYPE BIOMARKERS FOR PEMBROLIZUMAB TREATMENT RESPONSE
Source text for Eikon: ID:nPn8HR30Qa
Further company coverage: 328130.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lunit
See all newsBrief: Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development
Brief: Lunit Inc To Conduct Capital Increase Of 250 Billion Won
Brief: Lunit Announces Collaboration with Daiichi Sankyo on AI-Driven Biomarker Discovery
Brief: Lunit Inc - Awarded National Tender In France For Breast AI
Brief: Lunit Expands Partnership With Saudi Arabia's Largest Medical Group To Deploy Ai Chest X-Ray Solution